Search research articles
Contact Us
Filters
Showing results (31-40 of 64) with videos related to
Page
of 7
Sort By:
Cancer Chemotherapy and Pharmacology
|
May 1, 2009
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors
Keith M Skubitz, J Carlos Manivel, Denis R Clohisy, et al.
Experimental Cell Research
|
May 6, 2003
CD98-dependent homotypic aggregation is associated with translocation of protein kinase Cdelta and activation of mitogen-activated protein kinases
Jae Youl Cho, Keith M Skubitz, David R Katz, et al.
Journal of Pediatric Hematology/Oncology
|
March 1, 2014
An unusual case of Ewing sarcoma: a middle-aged woman with multiple recurrences over 36 years
Max J Gordon, J Carlos Manivel, Edward Y Cheng, et al.
BMC Medical Genomics
|
September 1, 2021
Multiple malignant tumors in a patient with familial chordoma, a case report
Nuttavut Sumransub, Paari Murugan, Shelly Marette, et al.
Cureus
|
March 11, 2024
Multifocal Desmoid-Type Fibromatosis: Case Series and Potential Relationship to Neuronal Spread
Keith M Skubitz, Shelly Marette, Paari Murugan, et al.
Spine
|
January 6, 2016
Response of Aneurysmal Bone Cyst to Denosumab
Keith M Skubitz, Justin C Peltola, Edward R Santos, et al.
Cureus
|
June 2, 2022
Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide
Keith M Skubitz, Bruce R Lindgren, Evidio Domingo-Musibay, et al.
Journal of Translational Medicine
|
December 2, 2005
Protein kinase activity is associated with CD63 in melanoma cells
Joji Iida, Amy P N Skubitz, James B McCarthy, et al.
Cancer Chemotherapy and Pharmacology
|
September 1, 2017
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value
Keith M Skubitz, Anne H Blaes, Suma H Konety, et al.
Cancers
|
July 27, 2022
Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
Keith M Skubitz, Evidio Domingo-Musibay, Bruce R Lindgren, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 64) with videos related to
Sort By:
Page
of 7
Cancer Chemotherapy and Pharmacology
|
May 1, 2009
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors
Keith M Skubitz, J Carlos Manivel, Denis R Clohisy, et al.
Experimental Cell Research
|
May 6, 2003
CD98-dependent homotypic aggregation is associated with translocation of protein kinase Cdelta and activation of mitogen-activated protein kinases
Jae Youl Cho, Keith M Skubitz, David R Katz, et al.
Journal of Pediatric Hematology/Oncology
|
March 1, 2014
An unusual case of Ewing sarcoma: a middle-aged woman with multiple recurrences over 36 years
Max J Gordon, J Carlos Manivel, Edward Y Cheng, et al.
BMC Medical Genomics
|
September 1, 2021
Multiple malignant tumors in a patient with familial chordoma, a case report
Nuttavut Sumransub, Paari Murugan, Shelly Marette, et al.
Cureus
|
March 11, 2024
Multifocal Desmoid-Type Fibromatosis: Case Series and Potential Relationship to Neuronal Spread
Keith M Skubitz, Shelly Marette, Paari Murugan, et al.
Spine
|
January 6, 2016
Response of Aneurysmal Bone Cyst to Denosumab
Keith M Skubitz, Justin C Peltola, Edward R Santos, et al.
Cureus
|
June 2, 2022
Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide
Keith M Skubitz, Bruce R Lindgren, Evidio Domingo-Musibay, et al.
Journal of Translational Medicine
|
December 2, 2005
Protein kinase activity is associated with CD63 in melanoma cells
Joji Iida, Amy P N Skubitz, James B McCarthy, et al.
Cancer Chemotherapy and Pharmacology
|
September 1, 2017
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value
Keith M Skubitz, Anne H Blaes, Suma H Konety, et al.
Cancers
|
July 27, 2022
Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
Keith M Skubitz, Evidio Domingo-Musibay, Bruce R Lindgren, et al.
Page
of 7